Patrick Forde

Prof. Patrick Forde is Prendergast Chair of Immuno-Oncology and Director of the Cancer Research program at Trinity College Dublin, Ireland. He is also part time Professor of Oncology at Johns Hopkins where he directed the lung cancer program from 2017 to 2024.  He has led the development of neoadjuvant immunotherapy for resectable lung cancer, initially exploring the role of single agent immunotherapy as neoadjuvant therapy and then as principal investigator of the CheckMate 816 trial which led to the approval internationally of neoadjuvant chemo-immunotherapy for stage II-III lung cancer. He serves on the scientific committee of the European Thoracic Oncology Platform and chaired lung cancer scientific program committees for ASCO 2026 and ESMO 2026. His research interests include development of novel therapeutics for earlier stage non-small cell lung cancer and for mesothelioma.